Fundraising Fox

Sam Tetlow

Founder

Co-founder, President & Executive Chair at Amalgent

Chapel Hill, North Carolina, United States

FoundedAmalgent

About

Sam Tetlow is Co-Founder and Chief Scientific Officer of Amalgent Therapeutics, where he leads development of a CNS therapeutic based on a combination of two small molecules and has secured $2.8M in SBIR funding as principal investigator. Through ZForm, LLC, he advises biopharma clients on development strategy, regulatory pathways, and non-dilutive funding, work that has contributed to over $20M in non-dilutive funding across small molecules, biologics, devices, and diagnostics. His earlier career includes more than a decade of stem cell research as a Howard Hughes Medical Institute Fellow at the University of Pennsylvania and a Research Professor at the University of Pittsburgh, followed by directing preclinical programs at Noveome Biotherapeutics.

Co-founder, President & Executive Chair at Amalgent

Intro paths

In turn, Sam can intro founders to Amalgent's investors below.

Co-founders at Amalgent

MMMalcolm Meyn
Malcolm MeynCo-founder & Chief Scientific Officer

Co-founder & Chief Scientific Officer at Amalgent

Intro paths

In turn, Sam can intro founders to Amalgent's investors below.

Co-founders at Amalgent

STSam Tetlow
Sam TetlowCo-founder, President & Executive Chair

Experience

  1. Amalgent TherapeuticsCo-Founder and Chief Scientific Officercurrent2020 — presentGreenville, North Carolina, United States
  2. ZForm, LLCFounder and Consultantcurrent2015 — presentChapel Hill, NC
  3. Noveome Biotherapeutics, Inc.Director, Preclinical Programs2011 — 2015Pittsburgh, Pennsylvania, United States
  4. University of PittsburghResearch Professor2002 — 2011Pittsburgh, Pennsylvania, United States
  5. Howard Hughes Medical InstituteHoward Hughes Fellow1997 — 2002University of Pennsylvania
  6. University of Pennsylvania School of MedicinePostdoctoral Researcher1997 — 2002Philadelphia, PA
  7. The University of ArizonaGraduate Student1991 — 1997

Skills & more

Chemistry, Manufacturing, and Controls (CMC)Small MoleculesProgram DevelopmentDrug DevelopmentStem Cells7Biochemistry9Cell Culture9Clinical Research4Molecular Biology11Clinical Trials4Cell Biology8Regenerative Medicine1
+12 moreWestern BlottingScienceMolecular CloningGeneticsCellProtein ExpressionImmunofluorescenceTransfectionEditingMicrosoft OfficeMicrosoft ExcelMicrosoft PowerPoint
  • Certificate in Biotechnology Project ManagementUniversity of Washington

From Sam's professional profile.

Frequently asked questions

Who is Sam Tetlow?
Sam Tetlow is Co-Founder and Chief Scientific Officer of Amalgent Therapeutics, where he leads development of a CNS therapeutic based on a combination of two small molecules and has secured $2.8M in SBIR funding as principal investigator. Through ZForm, LLC, he advises biopharma clients on development strategy, regulatory pathways, and non-dilutive funding, work that has contributed to over $20M in non-dilutive funding across small molecules, biologics, devices, and diagnostics. His earlier career includes more than a decade of stem cell research as a Howard Hughes Medical Institute Fellow at the University of Pennsylvania and a Research Professor at the University of Pittsburgh, followed by directing preclinical programs at Noveome Biotherapeutics.
Where does Sam Tetlow work?
Sam Tetlow is Co-founder, President & Executive Chair of Amalgent.
What companies did Sam Tetlow found?
Sam Tetlow founded Amalgent.
Where did Sam Tetlow go to school?
Sam Tetlow studied at University of Arizona (PhD, Plant Pathology and Microbial Genetics); The George Washington University School of Medicine and Health Sciences (MSHS, Regulatory Affairs); University of Washington (Certificate, Biotechnology Project Management).

Are you in our directory? — or find your own page and tap it there to see your paths to every investor.

Founder mafias

Same school

Shared employers